BioSpace News Archive

Accelus, a privately held medical technology company focused on accelerating the adoption of minimally invasive surgery as the standard of care in spine, announced the successful completion of the first cases utilizing its Remi™ robotic targeting and navigation platform with its LineSider™ posterior fixation system.

Cue Biopharma, Inc. announced that it will present at the Oppenheimer 32nd Annual Healthcare Conference being held virtually March 15-17.

Spectrum Pharmaceuticals today announced the appointment of Juhyun Lim to its Board of Directors.

Xeris Biopharma Holdings, Inc. today announced financial results for the fourth quarter and full-year 2021 and recent highlights.

Cognition Therapeutics will be presenting results from the clinical development program of CT1812, a small-molecule sigma-2 (σ-2) receptor modulator in development for Alzheimer’s disease and other neurodegenerative disorders.

Inari Medical, Inc. today announced the commencement of an underwritten public offering of 2,000,000 shares of its common stock.

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) today announced it has entered into an agreement with KBI Biopharma, Inc. (“KBI”) for the process transfer, process optimization and cGMP manufacturing of the Company’s intranasal vaccine candidate NT-CoV2-1.

Tempest Therapeutics, Inc. announced that management will present at the 32nd Annual Oppenheimer Healthcare Conference on Thursday, March 17, 2022 at 10:40 a.m. ET.

ExCellThera Inc. (ExCellThera), a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in next generation cell and gene therapies, announced today that the first patient has been dosed in its Phase I/II clinical trial of ECT-001 for the treatment of pediatric and young adults with high risk myeloid malignancies.

aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Company”), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the positive outcome of a Type B End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding its lead therapeutic candidate, efzofitimod (ATYR1923), for the treatment of pulmonary sarcoidosis.